173.90Open173.90Pre Close0 Volume10 Open Interest90.00Strike Price0.00Turnover157.72%IV4.00%PremiumDec 20, 2024Expiry Date163.74Intrinsic Value100Multiplier22DDays to Expiry10.16Extrinsic Value100Contract SizeAmericanOptions Type0.9978Delta0.0001Gamma1.55Leverage Ratio-0.0246Theta0.0547Rho1.54Eff Leverage0.0043Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet